Abstract:Despite a generally better prognosis than high-grade glioma (HGG), recurrence and malignant progression are the main causes for the poor prognosis and difficulties in the treatment of low-grade glioma (LGG). It is of great importance to learn about the risk factors and underlying mechanisms of LGG recurrence and progression. In this study, the transcriptome characteristics of four groups, namely, normal brain tissue and recurrent LGG (rLGG), normal brain tissue and secondary glioblastoma (sGBM), primary LGG (pLGG) and rLGG, and pLGG and sGBM, were compared using Chinese Glioma Genome Atlas (CGGA) and Genotype-Tissue Expression Project (GTEx) databases. In this study, 296 downregulated and 396 upregulated differentially expressed genes (DEGs) with high consensus were screened out. Univariate Cox regression analysis of data from The Cancer Genome Atlas (TCGA) yielded 86 prognostically relevant DEGs; a prognostic prediction model based on five key genes (HOXA1, KIF18A, FAM133A, HGF, and MN1) was established using the least absolute shrinkage and selection operator (LASSO) regression dimensionality reduction and multivariate Cox regression analysis. LGG was divided into high- and low-risk groups using this prediction model. Gene Set Enrichment Analysis (GSEA) revealed that signaling pathway differences in the high- and low-risk groups were mainly seen in tumor immune regulation and DNA damage-related cell cycle checkpoints. Furthermore, the infiltration of immune cells in the high- and low-risk groups was analyzed, which indicated a stronger infiltration of immune cells in the high-risk group than that in the low-risk group, suggesting that an immune microenvironment more conducive to tumor growth emerged due to the interaction between tumor and immune cells. The tumor mutational burden and tumor methylation burden in the high- and low-risk groups were also analyzed, which indicated higher gene mutation burden and lower DNA methylation level in the high-risk group, suggesting that with the accumulation of genomic mutations and epigenetic changes, tumor cells continued to evolve and led to the progression of LGG to HGG. Finally, the value of potential therapeutic targets for the five key genes was analyzed, and findings demonstrated that KIF18A was the gene most likely to be a potential therapeutic target. In conclusion, the prediction model based on these five key genes can better identify the high- and low-risk groups of LGG and lay a solid foundation for evaluating the risk of LGG recurrence and malignant progression.

Prognostic value of γ‐aminobutyric acidergic synapse-associated signature for lower-grade gliomas

Development and Verification of Glutamatergic Synapse-Associated Prognosis Signature for Lower-Grade Gliomas

Identification of robust diagnostic and prognostic gene signatures in different grades of gliomas: a retrospective study

Prognostic and Predictive Value of Immune-Related Gene Pair Signature in Primary Lower-Grade Glioma Patients

Identification and Validation of a Three-Gene Signature As a Candidate Prognostic Biomarker for Lower Grade Glioma

Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma

Identification of a Tumor Microenvironment-Related Eight-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas

Application of a risk score model based on glycosylation-related genes in the prognosis and treatment of patients with low-grade glioma

TGF-β Score based on Silico Analysis can Robustly Predict Prognosis and Immunological Characteristics in Lower-grade Glioma: The Evidence from Multicenter Studies

Comprehensive Characterization of a Novel E3-Related Gene Signature with Implications in Prognosis and Immunotherapy of Low-Grade Gliomas.

Peer Review #2 of "identification and Validation of a Three-Gene Signature As a Candidate Prognostic Biomarker for Lower Grade Glioma (V0.2)"

Development of a Prognostic Five-Gene Signature for Diffuse Lower-Grade Glioma Patients

Integrative Analysis of DNA Methylation and Gene Expression Identify a Three-Gene Signature for Predicting Prognosis in Lower-Grade Gliomas.

An Autophagic Gene‐based Signature to Predict the Survival of Patients with Low‐grade Gliomas

A lipid metabolism and immune-related gene signature for predicting the prognosis of human gliomas

Prognostic Value of an Autophagy-Related Five-Gene Signature for Lower-Grade Glioma Patients

Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy

A novel ARHGAP family gene signature for survival prediction in glioma patients

A novel risk score model based on fourteen chromatin regulators-based genes for predicting overall survival of patients with lower-grade gliomas

A novel Golgi related genes based correlation prognostic index can better predict the prognosis of glioma and responses to immunotherapy

Identification of a Five-Pseudogene Signature for Predicting Survival and Its Cerna Network in Glioma